End-of-day quote
Toronto S.E.
|
5-day change
|
1st Jan Change
|
- PTS
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
50.49
|
113
|
55.6
|
14.23
|
12.42
|
Enterprise Value (EV)
1 |
31.75
|
97.42
|
25.6
|
-0.7782
|
10.8
|
P/E ratio
|
-1.04
x
|
-2.83
x
|
-8.79
x
|
-0.96
x
|
-0.95
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11,015
x
|
11,300
x
|
418
x
|
17.3
x
|
10.6
x
|
EV / Revenue
|
6,927
x
|
9,742
x
|
192
x
|
-0.95
x
|
9.21
x
|
EV / EBITDA
|
-2.79
x
|
-6.76
x
|
-1.24
x
|
0.05
x
|
-0.86
x
|
EV / FCF
|
-3.29
x
|
-13.6
x
|
-2.23
x
|
0.1
x
|
-1.73
x
|
FCF Yield
|
-30.4%
|
-7.35%
|
-44.9%
|
1,010%
|
-57.7%
|
Price to Book
|
2.29
x
|
-202
x
|
1.87
x
|
0.87
x
|
3.62
x
|
Nbr of stocks (in thousands)
|
78,892
|
96,584
|
1,23,545
|
1,23,720
|
1,24,242
|
Reference price
2 |
0.6400
|
1.170
|
0.4500
|
0.1150
|
0.1000
|
Announcement Date
|
24/03/20
|
23/03/21
|
29/03/22
|
21/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0169
|
0.004584
|
0.01
|
0.133
|
0.821
|
1.172
|
EBITDA
1 |
-1.598
|
-11.38
|
-14.4
|
-20.67
|
-16.5
|
-12.62
|
EBIT
1 |
-1.645
|
-13.08
|
-16.85
|
-23.2
|
-18.4
|
-13.48
|
Operating Margin
|
-9,723.67%
|
-2,85,269.28%
|
-1,68,460%
|
-17,440.6%
|
-2,241.17%
|
-1,149.91%
|
Earnings before Tax (EBT)
1 |
-1.645
|
-46.15
|
-33.95
|
-6.14
|
-14.76
|
-13.03
|
Net income
1 |
-1.645
|
-44.57
|
-33.95
|
-6.14
|
-14.81
|
-13.03
|
Net margin
|
-9,723.67%
|
-9,72,220.55%
|
-3,39,460%
|
-4,616.54%
|
-1,804.38%
|
-1,111.69%
|
EPS
2 |
-0.7501
|
-0.6184
|
-0.4140
|
-0.0512
|
-0.1198
|
-0.1049
|
Free Cash Flow
1 |
-1.2
|
-9.651
|
-7.165
|
-11.49
|
-7.857
|
-6.234
|
FCF margin
|
-7,094.29%
|
-2,10,531.26%
|
-71,647.5%
|
-8,640.13%
|
-957.03%
|
-531.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/05/19
|
24/03/20
|
23/03/21
|
29/03/22
|
21/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.44
|
18.7
|
15.6
|
30
|
15
|
1.63
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.2
|
-9.65
|
-7.16
|
-11.5
|
-7.86
|
-6.23
|
ROE (net income / shareholders' equity)
|
-303%
|
-390%
|
-317%
|
-42.2%
|
-64.3%
|
-132%
|
ROA (Net income/ Total Assets)
|
-126%
|
-46.9%
|
-37.8%
|
-51%
|
-43.3%
|
-67.9%
|
Assets
1 |
1.301
|
95.02
|
89.87
|
12.04
|
34.24
|
19.2
|
Book Value Per Share
2 |
0.3600
|
0.2800
|
-0.0100
|
0.2400
|
0.1300
|
0.0300
|
Cash Flow per Share
2 |
0.1600
|
0.2500
|
0.1600
|
0.2400
|
0.0900
|
0.0300
|
Capex
1 |
0.2
|
6.71
|
0.95
|
1.67
|
0.68
|
0.61
|
Capex / Sales
|
1,199.34%
|
1,46,431.57%
|
9,520%
|
1,255.64%
|
82.83%
|
51.62%
|
Announcement Date
|
08/05/19
|
24/03/20
|
23/03/21
|
29/03/22
|
21/03/23
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +8.37% | 10TCr | | +11.97% | 4.39TCr | | -11.76% | 3.32TCr | | +79.34% | 2.94TCr | | -12.20% | 1.61TCr | | +4.00% | 1.47TCr | | -1.90% | 1.29TCr | | +178.17% | 1.05TCr | | +1.80% | 882.97Cr |
Biopharmaceuticals
|